Loading…
Kazia Therapeutics Limited is projected to rise to $14.58 by 2027, a +16% move from its current price of $12.62. KZIA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $12.16 | $12.62 | $13.10 | +0.02% |
| Aug 5 | $11.97 | $12.62 | $13.31 | +0.03% |
| Aug 6 | $11.83 | $12.63 | $13.47 | +0.05% |
| Aug 7 | $11.72 | $12.63 | $13.61 | +0.07% |
| Aug 8 | $11.62 | $12.63 | $13.73 | +0.08% |
| Aug 9 | $11.52 | $12.63 | $13.85 | +0.10% |
| Aug 10 | $11.44 | $12.63 | $13.95 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.44 | $12.63 | $13.95 | +0.12% |
| Week 2 | $11.00 | $12.65 | $14.55 | +0.24% |
| Week 3 | $10.67 | $12.66 | $15.04 | +0.35% |
| Week 4 | $10.40 | $12.68 | $15.46 | +0.47% |
| Week 5 | $10.17 | $12.69 | $15.85 | +0.59% |
| Week 6 | $9.97 | $12.71 | $16.20 | +0.71% |
| Week 7 | $9.79 | $12.72 | $16.54 | +0.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kazia Therapeutics Limited is an oncology-focused biotechnology company with operations in Israel. The lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer.
The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Kazia Therapeutics Limited (KZIA) is currently priced at $12.03. It has a market capitalization of $137.47M and is ranked 4034. The stock’s near‑term price dynamics are supported by technicals indicating bullish momentum, with key levels at $12.03 support and $14.69 resistance.
The 30‑day price range runs from $9.41 to $15.38, and annualized volatility stands at 70%. A year‑by‑year forecast accompanies current pricing, outlining expected moves from 2026 through 2050 with defined min, average, and max values and ROI figures.
A major floor 43.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 16.4% above — a clean break opens room to run.
A major ceiling 25.0% above — clearing it would confirm fresh momentum.
Key KZIA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KZIA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.47 | Buy | $12.63 | Sell |
| MA 10 | $13.00 | Sell | $12.82 | Sell |
| MA 20 | $13.11 | Sell | $13.04 | Sell |
| MA 50 | $13.07 | Sell | $12.84 | Sell |
| MA 100 | $11.65 | Buy | $11.85 | Buy |
| MA 200 | $9.76 | Buy | $10.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.23 | Neutral |
| Stoch RSI (14) | 25.38 | Neutral |
| CCI (20) | -66.45 | Neutral |
| Williams %R (14) | -77.04 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -6.10 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 22.96 | Neutral |
| TRIX (15) | -0.07 | Sell |
| Awesome (5,34) | -1.03 | Sell |
| Ultimate (7,14,28) | 34.50 | Neutral |
| Momentum (10) | -0.72 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 12.30 | Buy |
| ADX (14) | 11.38 | Neutral |
| ATR (14) | 0.46 | Info |
The near-term technical picture is bullish in sentiment. The RSI14 reads 40, with the 50-day simple moving average at $13.05 and the 200-day simple moving average at $9.70. Immediate support is at $12.03 and resistance at $14.69, framing a 30‑day range between $9.41 and $15.38.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.00 | $12.62 | $15.98 | 0% | Neutral | |
| $11.24 | $14.58 | $20.22 | +16% | Neutral | |
| $11.03 | $14.91 | $21.71 | +18% | Neutral | |
| $14.35 | $20.05 | $30.33 | +59% | Bullish | |
| $17.86 | $25.71 | $40.14 | +104% | Bullish | |
| $19.11 | $28.28 | $45.37 | +124% | Bullish | |
| $21.95 | $33.34 | $54.81 | +164% | Bullish | |
| $20.92 | $32.56 | $54.70 | +158% | Bullish | |
| $20.39 | $32.48 | $55.67 | +157% | Bullish | |
| $25.09 | $40.89 | $71.39 | +224% | Bullish | |
| $35.39 | $64.03 | $120.69 | +407% | Bullish | |
| $70.59 | $154.41 | $324.80 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.00 | $12.62 | $15.46 | +0.00% |
| September 2026 | $10.99 | $13.14 | $16.25 | +4.12% |
| October 2026 | $10.62 | $12.82 | $16.08 | -2.46% |
| November 2026 | $10.07 | $12.25 | $15.54 | -4.45% |
| December 2026 | $10.17 | $12.46 | $15.98 | +1.75% |
Click any year to see its month-by-month KZIA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, KZIA is projected to trade between $5.00 and $15.98, averaging $12.62 — a potential gain of 0% from today's $12.62. Price action looks broadly range-bound.
Kazia Therapeutics Limited's 2027 outlook centres on $14.58, within a $11.24 to $20.22 range. That is up +16% on the projected 2026 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, KZIA could reach as high as $21.71, with a base case around $14.91 and support toward $11.03 — roughly +18% from $12.62. Price action looks broadly range-bound.
Expect KZIA to range from $14.35 to $30.33 through 2029. The $20.05 average target implies a +59% move from current prices. That is up +35% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The KZIA price prediction for 2030 points to an average of $25.71 (low $17.86, high $40.14) — a potential gain of +104% on today's $12.62. Momentum favours further upside here.
In 2031, KZIA is projected to trade between $19.11 and $45.37, averaging $28.28 — a potential gain of +124% from today's $12.62. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Kazia Therapeutics Limited's 2032 outlook centres on $33.34, within a $21.95 to $54.81 range. That is up +18% on the projected 2031 average. That marks a +164% change versus current levels. Momentum favours further upside here.
By 2033, KZIA could reach as high as $54.70, with a base case around $32.56 and support toward $20.92 — roughly +158% from $12.62. Buyers look set to stay in control over this stretch.
Expect KZIA to range from $20.39 to $55.67 through 2034. The $32.48 average target implies a +157% move from current prices. That is 0% versus the projected 2033 average. Momentum favours further upside here.
The KZIA price prediction for 2035 points to an average of $40.89 (low $25.09, high $71.39) — a potential gain of +224% on today's $12.62. Buyers look set to stay in control over this stretch.
In 2040, KZIA is projected to trade between $35.39 and $120.69, averaging $64.03 — a potential gain of +407% from today's $12.62. That is up +57% on the projected 2035 average. Momentum favours further upside here.
Kazia Therapeutics Limited's 2050 outlook centres on $154.41, within a $70.59 to $324.80 range. That is up +141% on the projected 2040 average. That marks a +11.2x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in KZIA today (≈ 79.239303 KZIA) could be worth
$12,235.02
+$11,235.02 (+1124%) by 2050 · US Dollar
Based on the average projected KZIA price of $154.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KZIAwould be worth at today's price.
$1,000 invested in KZIA on Jul 31, 2025 (≈ 119.331741 KZIA) would be worth
$1,505.97
+$505.97 (+50.6%) today · 1.51× · US Dollar
Based on a KZIA entry price of $8.38 vs. today's $12.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.26 | $1,029.36 | +2.9% |
| 1 month ago | $13.39 | $942.49 | -5.8% |
| 3 months ago | $13.39 | $942.49 | -5.8% |
| 6 months ago | $6.2 | $2,035.48 | +103.5% |
| 1 year ago | $8.38 | $1,505.97 | +50.6% |
| All time (5.0y) ago | $455 | $27.74 | -97.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KZIA forecast.
Our base-case forecast reaches $25.00 around 2030.
Implied market cap at $25.00: $285.67M
The multi-year forecast points to a substantial upside trajectory. For 2026, the min price is $5.00, the avg price is $12.03, and the max price is $15.12, with ROI 0 and a NEUTRAL sentiment. In 2027 the avg rises to $13.28 (min $10.23, max $18.41) with ROI 10.3 and NEUTRAL sentiment; by 2028 the avg is $13.09 (min $9.69, max $19.05) with ROI 8.8.
The 2029 forecast shows a stronger rise to an avg of $16.90 (min $12.10, max $25.54) and ROI 40.5, with a BULLISH sentiment. By 2030 the avg is $21.19 (min $14.73, max $33.04) and ROI 76.1, still BULLISH; 2031 shows avg $23.16 (min $15.66, max $37.10) ROI 92.5, 2032 at avg $27.00 (min $17.80, max $44.32) ROI 124.4. The sequence continues with 2033 avg $25.68, 2034 avg $25.17, 2035 avg $31.06, all with solid bullish contours and double‑digit ROIs.
In 2040 the forecast projects an avg of $46.54 (min $25.80, max $87.57) with ROI 286.9, and by 2050 an avg of $107.40 (min $49.33, max $225.41) with ROI 792.8, continuing a BULLISH stance through the horizon. These are estimates and not guarantees, reflecting potential upside and inherent uncertainty in biotech equities.
Tap a question to reveal the answer.
The forecast shows an avg of "$21.19" in 2030, with a min of "$14.73" and a max of "$33.04", and a ROI of 76.1%. The sentiment is BULLISH.
Forecasts indicate a neutral stance in 2026 with an avg of "$12.03" and ROI 0, followed by bullish years through 2050, with the avg rising to "$21.19" by 2030 and to "$107.40" by 2050, and a max of "$225.41" in 2050. These are estimates and not guarantees.
Yes. The 2050 forecast shows an avg of "$107.40" and a max of "$225.41", indicating that prices above $100 are within the modeled upside.
The current price is "$12.03".
The 30-day range is from "$9.41" to "$15.38".
Kazia Therapeutics Limited Community Discussion
0Share your Kazia Therapeutics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.